Randomised controlled field study to evaluate the efficacy and clinical safety of a single 8 mg/kg injectable dose of marbofloxacin compared with one or two doses of 7.5 mg/kg injectable enrofloxacin for the treatment of Actinobacillus pleuropneumoniae infections in growing-fattening pigs in Europe

Porcine Health Management
E GrandemangeKlaus Hellmann

Abstract

Acute outbreaks of Actinobacillus pleuropneumoniae (APP) require rapid, effective, parenteral antimicrobial treatment. The efficacy and safety of a single, short-acting, high dose of marbofloxacin (Forcyl® swine 160 mg/mL) compared with 1 or 2 doses of 7.5 mg/kg enrofloxacin in APP outbreaks in European farms was studied. A controlled, randomised block, blinded, multicentre, field study was conducted on four farms with acute respiratory disease associated with APP. Animals with clinical signs of respiratory disease were allocated similarly to intramuscular treatments of either a single dose 8 mg/kg marbofloxacin on day 0 or, 7.5 mg/kg enrofloxacin (Baytril 1nject®) on day 0 and again on day 2, if clinical signs had not improved. The results were similar for intention to treat (242 pigs) and per protocol populations (239 pigs). On day 0, all pigs had pyrexia (means, 40.6 °C), moderate to severe clinical signs (depression, cough, dyspnoea). Following treatment, animals improved rapidly and on day 7, clinical signs were absent or mild in all pigs and mean temperatures for each treatment were <39.5 °C (P > 0.05). The primary efficacy criterion, animals cured, for marbofloxacin and enrofloxacin was 81.8 and 81.4% on day 7, and 84.2 ...Continue Reading

References

Jan 21, 2000·The Veterinary Journal·A N Rycroft, L H Garside
Nov 29, 2001·Journal of Veterinary Diagnostic Investigation : Official Publication of the American Association of Veterinary Laboratory Diagnosticians, Inc·S OliveiraC Pijoan
Mar 24, 2004·Veterinary Microbiology·Boudewijn CatryFreddy Haesebrouck
Jul 6, 2004·Journal of Microbiological Methods·Dongyou LiuFrank W Austin
Mar 7, 2007·The Veterinary Journal·Lars MoorkampElisabeth Grosse Beilage
Mar 4, 2008·The Veterinary Record·A PalzerK Heinritzi
Feb 26, 2010·The Journal of Antimicrobial Chemotherapy·Stefan SchwarzWim Gaastra
Mar 6, 2010·Handbook of Experimental Pharmacology·Marilyn Martinez, Peter Silley
Nov 23, 2011·Veterinary Microbiology·Michele VanniLuigi Intorre
Mar 19, 2016·BioMed Research International·Ijaz AhmadZonghui Yuan

❮ Previous
Next ❯

Citations

Dec 7, 2017·Frontiers in Pharmacology·Zhixin LeiQigai He
Oct 31, 2017·Transboundary and Emerging Diseases·E L SassuI Hennig-Pauka
Jun 27, 2018·Journal of the South African Veterinary Association·Yigit KacarZafer Mecitoglu
Jun 23, 2020·The Journal of Veterinary Medical Science·Moe IjiriSeiji Hobo

❮ Previous
Next ❯

Methods Mentioned

BETA
bronchoalveolar lavage
PCR

Software Mentioned

SAS®

Related Concepts

Related Feeds

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Allergy & Infectious Diseases

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.

Allergy & Infectious Diseases (ASM)

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.